Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05873062 · ClinicalTrials.gov registry record · Phase 1
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK
A Phase 1 study, sponsored by Autifony Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05873062: Completed Phase 1 study, sponsored by Autifony Therapeutics Limited.
NCT05873062 is a Phase 1 study that has completed, run by Autifony Therapeutics Limited. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05873062, a Phase 1 study, has completed, sponsored by Autifony Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, crossover study to assess the safety, tolerability, and pharmacokinetics of single doses of AUT00201 at 100 mg or matching placebo in patients with myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK).
Interventions
- DRUG Placebo
- DRUG AUT00201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-05-12 |
| Est. Completion | 2024-05-01 |
| Phase | Phase 1 |
What the finished NCT05873062 record still lists
NCT05873062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05873062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05873062 about?
NCT05873062 is a clinical study titled "Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK". A randomized, double-blind, placebo-controlled, crossover study to assess the safety, tolerability, and pharmacokinetics of single doses of AUT00201 at 100 mg or matching placebo in patients with myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK).
What is the current status of trial NCT05873062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-05-12. Estimated completion is 2024-05-01.
What interventions are being tested in trial NCT05873062?
The interventions under investigation include: Placebo (DRUG), AUT00201 (DRUG).
Who is sponsoring clinical trial NCT05873062?
This trial is sponsored by Autifony Therapeutics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05873062's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI